Analyst consensus rating
Aktis Oncology Analyst Rating: Strong Buy
AKTS is rated Strong Buy by 8 analysts with a $34.81 target. As of 2026-08-31.
Direct answer
Aktis Oncology's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $34.81.
Forecast evidence checked August 31, 2026.
Get free Aktis Oncology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $25.78
- Average price target
- $34.81
- High price target
- $40.00
- Low price target
- $31.50
- Low target gap
- +22.2%
- Target upside
- +35%
- High target gap
- +55.2%
- Target range width
- 33%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aktis Oncology?
Aktis Oncology has a verified Strong Buy consensus. The same dataset has an average price target of $34.81.
How far are Aktis Oncology's low and high targets from the recorded price?
The low target implies +22.2%, while the high target implies +55.2%.
How many analysts are included in Aktis Oncology's consensus?
The verified consensus includes 8 analysts.
How is Aktis Oncology's target upside or downside calculated?
The average target of $34.81 is divided by the recorded price of $25.78, then one is subtracted to produce +35%. This does not guarantee a future return.
When was Aktis Oncology's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.